

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaRosa et al.
Serial No. : 10/766,773
Filed : January 27, 2004

Art Unit : 1648
Examiner : Agnieszka Boesen

Title : HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 3.73(b) AND 1.321(b)

Pursuant to 37 C.F.R. § 3.73(b), Millennium Pharmaceuticals, Inc., a corporation, certifies that it is the assignee of the entire right, title, and interest in the above-referenced application by virtue of:

☒ A chain of title from the inventors of the above-referenced patent application to the current assignee as shown below:

1. From the inventors to Millennium Pharmaceuticals, Inc. The document was recorded in the Patent and Trademark Office at Reel 011196, Frame 0894, on October 23, 2000.
2. From the inventors to Medical Research Council Technology. The document was recorded in the Patent and Trademark Office at Reel 011196, Frame 0853, on October 23, 2000.
3. From Medical Research Council Technology to Millennium Pharmaceuticals, Inc. The document was recorded in the Patent and Trademark Office at Reel 011199, Frame 0876, on October 23, 2000.

To the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Pursuant to 37 C.F.R. § 1.321(b), and to obviate a double patenting rejection, the assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-referenced application subsequent to the expiration date of U.S. Patent Nos.: 6,312,689 provided that any patent granted on the above-referenced application shall be enforceable only for and during such period that it is commonly owned with U.S. Patent Nos.: 6,312,689.

The assignee identified above does not disclaim any terminal part of any patent granted on the above-referenced application prior to the expiration date of the full statutory term of U.S. Patent No.: 6,312,689 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above. Assignee herein does not disclaim or otherwise affect any part of U.S. Patent No.: 6,312,689.

This disclaimer runs with any patent granted on the above application and is binding upon the grantee, its successors or assigns.


Enclosed is a check for \$130 for the required fee pursuant to 37 C.F.R. § 1.20(d). Please apply any other charges or credits to Deposit Account No. 06-1050.

Applicant : LaRosa et al.
Serial No. : 10/766,773
Filed : January 27, 2004
Page : 3 of 3

Attorney's Docket No.: 10448-217002 / MPI98-
129CP2RCEDV1

Respectfully submitted,

Date: 2/6/07



Laurie Butler Lawrence
Reg. No. 46,593

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21550878.doc